Maria Vonotna
After four consecutive years of underperformance, biotech stocks are among the most unloved segments in the market. Major industry benchmarks SPDR S&P Biotech ETF (NYSEARCA:XBI) and the iShares Biotechnology ETF (NASDAQ:IBB) have both trailed the S&P 500 (